Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
08:00am, Wednesday, 18'th Feb 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
12:35pm, Monday, 16'th Feb 2026
CDNA shares climb after AlloHeme data show early AML/MDS relapse detection, backing its Transplant+ expansion into cell therapy markets.
Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
06:08pm, Sunday, 15'th Feb 2026
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profit
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript
04:24pm, Thursday, 12'th Feb 2026
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
04:01pm, Tuesday, 10'th Feb 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
07:05am, Tuesday, 03'rd Feb 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026
03:16am, Sunday, 01'st Feb 2026
CareDx's President and CEO sold 19,480 shares over two days, totaling approximately $412,200 at an average price of $21.16 per share. The transaction reduced the CEO's direct holdings by 3.16%, leavin
CareDx President and CEO Sells 19,000 Shares for $412,000
09:59am, Friday, 30'th Jan 2026
19,480 shares directly sold for a total of ~$412,200 (weighted average price $21.16) across two transactions on Jan. 21 and Jan. 22, 2026. The sale represented 3.16% of direct holdings, reducing direc
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
04:05pm, Tuesday, 27'th Jan 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of cli
CareDx (NASDAQ:CDNA) CEO John Walter Hanna, Jr. Sells 10,156 Shares
04:39am, Wednesday, 21'st Jan 2026
CareDx, Inc. (NASDAQ: CDNA - Get Free Report) CEO John Walter Hanna, Jr. sold 10,156 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an ave
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Recommendation of “Hold” from Analysts
01:22am, Friday, 16'th Jan 2026
CareDx, Inc. (NASDAQ: CDNA - Get Free Report) has been given an average rating of "Hold" by the nine brokerages that are presently covering the stock, MarketBeat reports. Six research analysts have ra
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
07:05am, Monday, 12'th Jan 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
07:05am, Wednesday, 07'th Jan 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 26'th Dec 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c
